Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.

Sato, H; Miyata, Y; Inoue, H; Tanaka, A; Sagara, H

Sato, H; Miyata, Y; Inoue, H; Tanaka, A; Sagara, H.

Afiliação

Sato H; Department of Internal Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.
Miyata Y; Department of Internal Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.
Inoue H; Department of Internal Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.
Tanaka A; Department of Internal Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.
Sagara H; Department of Internal Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.

J Investig Allergol Clin Immunol ; 31(5): 459-460, 2021 Oct 25.

Article em En | MEDLINE | ID: mdl-33502319

Assuntos

Antiasmáticos; Asma; Eosinofilia Pulmonar; Antiasmáticos/uso terapêutico; Anticorpos Monoclonais Humanizados/uso terapêutico; Asma/tratamento farmacológico; Eosinófilos; Humanos; Eosinofilia Pulmonar/tratamento farmacológico

Palavras-chave

Anti-IL-5 monoclonal antibody; Asthma; Chronic eosinophilic pneumonia; Extended interval dosing; Mepolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Eosinofilia Pulmonar / Asma / Antiasmáticos Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google